Why Invest with Us?

Timely Opportunity

AI in Life Sciences
M&A Momentum
Sustainability Push
Women's Health Impact

Unique Edge

20+ Years in the Making
Integrated Innovation Hub
Proven Founders & Operators

Our Investment Thesis

We back pre-seed and seed stage companies with transformative technologies. Our pipeline includes:

Regenerative micro-RNA therapeutics for heart disease
AI-powered brain organoids for drug discovery
Continuous-flow biomanufacturing for cell culture media

Track Record of Success

Vaporox

$7.7M Seed+ | FDA-cleared wound care tech | Gen-2 device launched 2024
‍

Nymbl Science

Panel participation slot


‍

Synthio Chemicals

$4M Series A + $8.2M DoD contract | Green chemistry
‍
‍

Realvolve

Acquired in 2024 | AI CRM platform for real estate professionals
‍

Due Diligence & Deal Flow

400+

Inbound applications

300+

Partner referrals

300+

Targeted outreach

Fund Overview

$50M
‍

Fund Size

10 years
‍

Term

10 years
‍

Investment Period

$500K
‍

Min. Investment

15–20% IRR,
4–6x MOIC

Target Returns

2% / 20%
‍

Mgmt Fee / Carry

Fund Overview

Richard Lin, PhD
Founder & Startup Advisor
Leah Villegas, PhD
Investor & Entrepreneur
MyPhuong Le, PhD
Biotech Innovator
Wendy Charles, PhD
Digital Health Scientist
Kevin Buckley, JD
IP & Regulatory Expert

Let’s Talk Impact

Contact: hub@aquillius.com





‍

Aquillius is committed to fostering a collaborate ecosystem to support and accelerate startups.

Contact Address
10918 Technology Pl
San Diego, CA 92127
hub@aquillius.com
(858) 533-7500
Quick link
Privacy Policy
Terms of Use
House Rules
Visitor Agreement
Pitch Agreement
About Us
Blog
Copyright © 2025 Aquillius Corporation